Ran Ziskind
CEO
IR-Med
IR-Med develops a spectrographic AI-based technology platform for non-invasive biomarker analysis at the point of care. This handheld technology provides real-time assessment of blood and tissue to support clinical decision-making. Applications include early detection of pressure injuries, diabetic foot ulcers, and non-invasive drug level monitoring.
Updated 5 months ago
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Diagnosing conditions like pressure injuries and diabetic foot ulcers often relies on subjective visual assessment, which can lead to delayed detection and inconsistent treatment. Furthermore, differentiating between viral and bacterial pediatric ear infections or accurately monitoring drug levels in patients typically requires invasive procedures or laboratory analysis, creating barriers to timely and accessible care.
Solution
IR-Med provides a platform of non-invasive diagnostic devices utilizing spectrographic AI technology for real-time biomarker assessment. Their handheld devices offer healthcare professionals objective decision support for a range of conditions, including pressure injuries, diabetic foot ulcers, pediatric ear infections, and drug level monitoring. By analyzing subsurface tissue and fluid biomarkers, IR-Med's technology aims to improve patient care through earlier detection, more precise diagnoses, and personalized treatment strategies, while also reducing the need for invasive procedures.
Target Audience
The primary target audience includes healthcare professionals such as clinicians, nurses, and pediatricians who require objective, real-time diagnostic tools for patient assessment and treatment planning.
Features
- Handheld devices employing infrared (IR) spectroscopy for non-invasive analysis of subcutaneous tissue and bodily fluids.
- AI-driven algorithms that process spectral data to identify specific biomarkers and assess tissue conditions.
- Applications include early detection of pressure injuries (PressureSafe™), diabetic foot ulcers (DiaSafe™), and differentiation of viral vs. bacterial pediatric ear infections (NoBiotics™).
- Capability for real-time monitoring of drug levels in blood without requiring blood draws.
- Skin-color agnostic technology designed to ensure equitable diagnostic accuracy across diverse patient populations.
- Patents secured for the core AI-driven platform technology related to non-invasive tissue analysis.
- Point-of-care decision support system designed to integrate into clinical workflows.